MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Fluoroquinolones]]
			[[Category:Antibacterials]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #231

2026-05-23T04:00:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #231

New page

{{MedTemplate
| generic = Levofloxacin
| brand = Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix
| structure =
| classes = [[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]], [[:Category:Antibacterials|Antibacterial]]
| uses = <vote slug="cap-use">Community-acquired pneumonia</vote>, <vote slug="acute-bacterial-sinusitis-use">Acute bacterial sinusitis</vote>, <vote slug="complicated-uti-use">Complicated UTI / pyelonephritis</vote>, <vote slug="bacterial-prostatitis-use">Bacterial prostatitis</vote>, <vote slug="anthrax-prophylaxis-use">Anthrax prophylaxis and treatment</vote>, <vote slug="bacterial-conjunctivitis-use">Bacterial conjunctivitis/keratitis (topical)</vote>
| starting_dose = 500-750 mg PO/IV once daily
| preparations = 250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions
| fda_max = 750 mg/d
| pill_id =
| routes = Oral, IV, topical ophthalmic
| onset = Hours
| duration = 24 hours
| halflife = ~6-8 hours<ref name="levaquin-label">FDA Prescribing Information, Levaquin (levofloxacin), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s072,020635s075,021721s041lbl.pdf</ref>
| bioavailability = ~99% (oral; matched 1:1 IV-to-PO conversion)<ref name="levaquin-label" />
| pregnancy = '''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis<ref name="levaquin-label" />
| mechanism = <vote slug="levofloxacin-mech-claim">Levofloxacin (the L-enantiomer of ofloxacin) inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking supercoiling and decatenation required for DNA replication; the result is bactericidal.</vote> Among "respiratory fluoroquinolones" (with moxifloxacin and gemifloxacin) — broader S. pneumoniae and atypical coverage than ciprofloxacin, making it more useful in CAP. QT prolongation, hypoglycemia, and aortic dissection signals are recognized class effects<ref name="levaquin-label" />.
}}

== References ==
<references />

Levofloxacin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #231